12:33 PM EDT, 10/14/2024 (MT Newswires) -- Novartis ( NVS ) has terminated a Phase 2 trial of its LTP001 for idiopathic pulmonary fibrosis, according to data available on ClinicalTrials.gov.

A Novartis ( NVS ) spokesperson confirmed the decision to Fierce Biotech, adding that LTP001 will continue to be developed for pulmonary arterial hypertension.

"Novartis ( NVS ) has made the decision to end the early ph2 study of LTP001," the spokesperson told Fierce Biotech. "We continue to advance the SMURF1 inhibitor in development for its lead indication in pulmonary arterial hypertension (PAH), and will continue to evaluate future potential for IPF. There have been no concerning or new safety signals observed to date."

Novartis ( NVS ) did not immediately respond to MT Newswires' request for comment.

Price: 116.17, Change: -0.05, Percent Change: -0.04